The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009  a retrospective analysis

Nell-Duxneuner, Valerie; Schroeder, Y.; Reichardt, Berthold; Bucsics, Anna

doi:10.5414/cp201707

Cited by 15 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This potential for decrease in the number of patients being interviewed together with the commonly known reasons of therapy discontinuation, such as loss of efficacy and adverse events, could have contributed to the high withdraw rate observed at the 12-month follow-up [15,18]. Other studies have shown that the 1-year anti-TNF drug survival can range between 70% and 83% among AS patients [27,28].…”

Section: Discussionmentioning

confidence: 99%

Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Survival rates extracted from national registries have been used as a surrogate marker of efficacy, but controversial results have been reported. Data from the Austrian national register show better 2-year survival rates with etanercept than with adalimumab or infliximab,23 while the Danish national register shows no statistically significant differences between the three drugs 24. Overall drug survival for patients with rheumatoid arthritis, psoriatic arthritis, or AS was better for etanercept than for infliximab or adalimumab in the Norwegian registry,25 but this difference no longer exists when analyzing only first anti-TNF treatments.…”

Section: Efficacy Of Etanercept In Ankylosing Spondylitismentioning

confidence: 99%

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Gallego¹,

Santos-Ramírez²,

Santos-Soler³

et al. 2013

PPA

View full text Add to dashboard Cite

To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn’s disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.

show abstract

“…A retrospective review of the use of anti TNF alpha inhibitors in patients in Austria with ankylosing spondylitis showed that whilst patients were treated most often with adalimumab, patients on etanercept showed the lowest switching rate and the longest 1-and 2-year retention rate (122).…”

mentioning

confidence: 99%

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Godman

Malmström

Diogène³

et al. 2014

Expert Review of Clinical Pharmacology

Self Cite

110

130

View full text Add to dashboard Cite

Are new models needed to optimise the utilisation of new medicines to sustain healthcare systems?Godman B 1,2,3 , Malmström RE 4 , Diogene E 5 , Gray A 6 , Jayathissa S 7 , Timoney A 8 , Acurcio FA 9,10 , Alkan A 11 , Brzezinska A 12 , Bucsics A 13 , Campbell S 14,15 AbstractIntroduction: Medicines have made an appreciable contribution to improving health. However, even high income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimise their use. Objective: Review case histories among health authorities to improve the utilisation and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. Challenges and proposed models: A number of issues and challenges have been identified including the limited innovation level of new medicines alongside increasing requested prices for their reimbursement especially for oncology, orphan diseases, diabetes and HCV. Models centre on the three pillars of pre-, peri, and post-launch including critical drug evaluation and multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure Discussion: Proposed models which involve all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

show abstract

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 a retrospective analysis

Abstract: Patients with Ankylosing Spondylitis starting on TNF-inhibiting therapy in Austria in 2007 were treated most often with Adalimumab, while Etanercept showed the lowest switching rate and the longest 1- and 2-year drug survival.

Cited by 15 publications

References 0 publications

Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil

Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Contact Info

Product

Resources

About

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009  a retrospective analysis

Abstract: Patients with Ankylosing Spondylitis starting on TNF-inhibiting therapy in Austria in 2007 were treated most often with Adalimumab, while Etanercept showed the lowest switching rate and the longest 1- and 2-year drug survival.

Cited by 15 publications

References 0 publications

Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil

Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Contact Info

Product

Resources

About

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 a retrospective analysis